All Stories

  1. Towards more reliable experimental models for pancreatic cancer
  2. Cyclohexanediamine Triazole (CHDT) Functionalization Enables Labeling of Target Molecules with Al18F/68Ga/111In
  3. Programmable Release of Chemotherapeutics from Ferrocene‐Based Injectable Hydrogels Slows Melanoma Growth
  4. Carborane Conjugates with Ibuprofen, Fenoprofen and Flurbiprofen: Synthesis, Characterization, COX Inhibition Potential and In Vitro Activity
  5. 64 Cu tumor labeling with hexadentate picolinic acid‐based bispidine immunoconjugates
  6. Impact of Viscosity on Human Hepatoma Spheroids in Soft Core–Shell Microcapsules
  7. Preclinical evaluation of an 18F-labeled Nε-acryloyllysine piperazide for covalent targeting of transglutaminase 2
  8. Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments
  9. Towards an advanced clinical use of radiocopper in cancer theranostics
  10. Radiosynthesis and biological evaluation of [18F]AG-120 for PET imaging of the mutant isocitrate dehydrogenase 1 in glioma
  11. Lysyl Oxidases as Targets for Cancer Therapy and Diagnostic Imaging
  12. Anti-Cancer Prodrug Cyclophosphamide Exerts Thrombogenic Effects on Human Venous Endothelial Cells Independent of CYP450 Activation—Relevance to Thrombosis
  13. Comparative Saturation Binding Analysis of 64Cu-Labeled Somatostatin Analogues Using Cell Homogenates and Intact Cells
  14. Synthesis and In Vitro Biological Evaluation of p-Carborane-Based Di-tert-butylphenol Analogs
  15. Reactivating damaged motor neurons using magnetic fields
  16. Preclinical Characterization of the 177Lu-Labeled Prostate Stem Cell Antigen (PSCA)-Specific Monoclonal Antibody 7F5
  17. Isonimesulide and Its Carborane Analogues as Isoform‐Selective COX Inhibitors and Antitumor Agents
  18. Carborane‐based Tebufelone Analogs and their Biological Evaluation In Vitro
  19. Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells
  20. Metastatic pheochromocytoma and paraganglioma: Somatostatin receptor 2 expression, genetics and therapeutic responses
  21. Shell engineering in soft alginate‐based capsules for culturing liver spheroids
  22. Dipeptide-Derived Alkynes as Potent and Selective Irreversible Inhibitors of Cysteine Cathepsins
  23. A self-assembled dynamic extracellular matrix-like hydrogel system with multi-scale structures for cell bioengineering applications
  24. Impedimetric Nanobiosensor for the Detection of SARS-CoV-2 Antigens and Antibodies
  25. Microdialysis Reveals Anti-Inflammatory Effects of Sulfated Glycosaminoglycanes in the Early Phase of Bone Healing
  26. Solid-Phase Parallel Synthesis of Dual Histone Deacetylase-Cyclooxygenase Inhibitors
  27. Prostaglandins and the Lung
  28. The Impact of Nε-Acryloyllysine Piperazides on the Conformational Dynamics of Transglutaminase 2
  29. Modulating the Renal Clearance of Targeted Radiopharmaceuticals
  30. Carborane-based Compounds in Dual Inhibitor Design
  31. Pheochromocytoma radionuclide theranostics and radiation transcriptomics
  32. Carborane Analogues of Fenoprofen Exhibit Improved Antitumor Activity
  33. Impact of Sulfated Hyaluronan on Bone Metabolism in Diabetic Charcot Neuroarthropathy and Degenerative Arthritis
  34. Toward Personalized Medicine: One Chelator for Imaging and Therapy with Lutetium-177 and Actinium-225
  35. Targeting neuropeptide receptors for cancer imaging
  36. New link between dietary phosphate and coronary heart disease
  37. NO• donors in cancer therapy
  38. Case report: Incidentally discovered case of pheochromocytoma as a cause of long COVID-19 syndrome
  39. Better understanding the metabolic stability of radiotracers
  40. Carboranyl Analogues of Mefenamic Acid and Their Biological Evaluation
  41. Application of a Fluorescence Anisotropy-Based Assay to Quantify Transglutaminase 2 Activity in Cell Lysates
  42. The Role of Transglutaminase 2 in the Radioresistance of Melanoma Cells
  43. Acceleration to the next level
  44. Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures
  45. CRISPR/Cas9 Mediated Knockout of Cyclooxygenase-2 Gene Inhibits Invasiveness in A2058 Melanoma Cells
  46. A Self‐Assembled Matrix System for Cell‐Bioengineering Applications in Different Dimensions, Scales, and Geometries
  47. Targeting estrogen receptors in melanoma
  48. Targeting bone with copper radionuclides
  49. “Clickable” Albumin Binders for Modulating the Tumor Uptake of Targeted Radiopharmaceuticals
  50. Solid-Phase Synthesis of Selectively Mono-Fluorobenz(o)ylated Polyamines as a Basis for the Development of 18F-Labeled Radiotracers
  51. Hybrid agents for multimodal imaging
  52. Men who stare at bone: multimodal monitoring of bone healing
  53. Radiolabelled Cyclic Bisarylmercury: High Chemical and in vivo Stability for Theranostics
  54. Modulation of γ-Secretase Activity by a Carborane-Based Flurbiprofen Analogue
  55. Conductive Hydrogels with Dynamic Reversible Networks for Biomedical Applications
  56. Immunocompatibility and non-thrombogenicity of gelatin-based hydrogels
  57. Convergent synthesis of diversified reversible network leads to liquid metal-containing conductive hydrogel adhesives
  58. Development of an 18F-Labeled Irreversible Inhibitor of Transglutaminase 2 as Radiometric Tool for Quantitative Expression Profiling in Cells and Tissues
  59. Development of a ghrelin receptor inverse agonist for positron emission tomography
  60. The transCampus Metabolic Training Programme Explores the Link of SARS-CoV-2 Virus to Metabolic Disease
  61. Response of Endothelial Cells to Gelatin-Based Hydrogels
  62. Pseudohypoxia causes radioresistance
  63. Screening Arrays of Laminin Peptides on Modified Cellulose for Promotion of Adhesion of Primary Endothelial and Neural Precursor Cells
  64. A modular, injectable, non-covalently assembled hydrogel system features widescale tunable degradability for controlled release and tissue integration
  65. The Pyrazolo[3,4-d]pyrimidine-Based Kinase Inhibitor NVP-BHG712: Effects of Regioisomers on Tumor Growth, Perfusion, and Hypoxia in EphB4-Positive A375 Melanoma Xenografts
  66. The influence of different artificial extracellular matrix implant coatings on the regeneration of a critical size femur defect in rats
  67. Pseudohypoxia promotes metastasis
  68. Recent Insights in Barium-131 as a Diagnostic Match for Radium-223: Cyclotron Production, Separation, Radiolabeling, and Imaging
  69. Radiopharmaceutical Cancer Research goes 3D
  70. Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas
  71. Fighting Cancer: Targeting the Eph Receptor Tyrosine Kinase Subfamily
  72. Comparison of manual and automated ventricle segmentation in the maternal immune stimulation rat model of schizophrenia
  73. The sigma-1 receptor: Potential role in the modulation of cellular radiation sensitivity
  74. Adjuvant Drug-Assisted Bone Healing: Advances and Challenges in Drug Delivery Approaches
  75. Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells
  76. Regulation of bone regeneration
  77. Adjuvant drug-assisted bone healing: Part I – Modulation of inflammation
  78. Adjuvant drug-assisted bone healing: Part II – Modulation of angiogenesis
  79. Adjuvant drug-assisted bone healing: Part III – Further strategies for local and systemic modulation
  80. Synthesis, radiolabelling and initial biological characterisation of 18F-labelled xanthine derivatives for PET imaging of Eph receptors
  81. Deuteration versus ethylation – strategies to improve the metabolic fate of an 18F-labeled celecoxib derivative
  82. Fluorescent mouse pheochromocytoma spheroids expressing hypoxia-inducible factor 2 alpha: Morphologic and radiopharmacologic characterization
  83. Active Targeting of Dendritic Polyglycerols for Diagnostic Cancer Imaging
  84. Bone healing made visible
  85. Synthesis and Cyclooxygenase Inhibition of Sulfonamide-Substituted (Dihydro)Pyrrolo[3,2,1-hi]indoles and Their Potential Prodrugs
  86. Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician
  87. Characterization of Tissue Transglutaminase as a Potential Biomarker for Tissue Response toward Biomaterials
  88. A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR
  89. Radiochemical and radiopharmacological characterization of a 64 Cu-labeled α-MSH analog conjugated with different chelators
  90. Targeting Cyclooxygenase-2 in Pheochromocytoma and Paraganglioma: Focus on Genetic Background
  91. Cytocompatible, Injectable, and Electroconductive Soft Adhesives with Hybrid Covalent/Noncovalent Dynamic Network
  92. Instant kit preparation of 68Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [68Ga]Ga-DATA-TOC
  93. Carboranyl Analogues of Ketoprofen with Cytostatic Activity against Human Melanoma and Colon Cancer Cell Lines
  94. Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index
  95. Synthesis and preliminary radiopharmacological characterisation of an 11 C-labelled azadipeptide nitrile as potential PET tracer for imaging of cysteine cathepsins
  96. Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif2α in Pheochromocytoma Cells
  97. Limited importance of EphrinA1–ligand, Src kinase, and focal adhesion kinase in EphA2-mediated regulation of metastasis in Mel-Juso and A375 human melanoma cells
  98. Regulation of A375 melanoma cell adhesion and migration by EphB4 and EphrinB2 – insights from co-culture experiments
  99. Cover Feature: Carboranyl Analogues of Celecoxib with Potent Cytostatic Activity against Human Melanoma and Colon Cancer Cell Lines (ChemMedChem 3/2019)
  100. Carboranyl Analogues of Celecoxib with Potent Cytostatic Activity against Human Melanoma and Colon Cancer Cell Lines
  101. Fluorine-18 Labeling of S100 Proteins for Small Animal Positron Emission Tomography
  102. One-Pot Cascade Synthesis of Pyrazole Based Isosteres of Valdecoxib by a [3+2] Cycloaddition Sequence and Evaluation of Their Cox Inhibitory Activity
  103. Strain-specific metastatic phenotypes in pheochromocytoma allograft mice
  104. Diverse effects of phospholipase A2 receptor expression on LNCaP and PC-3 prostate cancer cell growth in vitro and in vivo
  105. Synthesis, 18F-labelling and radiopharmacological characterisation of the C-terminal 30mer of Clostridium perfringens enterotoxin as a potential claudin-targeting peptide
  106. Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells
  107. Exploring pitfalls of 64Cu-labeled EGFR-targeting peptide GE11 as a potential PET tracer
  108. Causative treatment of acid aspiration induced acute lung injury – Recent trends from animal experiments and critical perspective
  109. From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo
  110. Evaluation of Fluorine-18-Labeled α1(I)-N-Telopeptide Analogs as Substrate-Based Radiotracers for PET Imaging of Melanoma-Associated Lysyl Oxidase
  111. Synthesis, Characterization, and Initial Biological Evaluation of [99m Tc]Tc-Tricarbonyl-labeled DPA-α-MSH Peptide Derivatives for Potential Melanoma Imaging
  112. Nε-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure–Activity Relationships, and Pharmacokinetic Profiling
  113. Bridging from Brain to Tumor Imaging: (S)-(−)- and (R)-(+)-[18F]Fluspidine for Investigation of Sigma-1 Receptors in Tumor-Bearing Mice
  114. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology
  115. Overexpression of Receptor Tyrosine Kinase EphB4 Triggers Tumor Growth and Hypoxia in A375 Melanoma Xenografts: Insights from Multitracer Small Animal Imaging Experiments
  116. Novel valdecoxib derivatives by ruthenium(ii)-promoted 1,3-dipolar cycloaddition of nitrile oxides with alkynes – synthesis and COX-2 inhibition activity
  117. Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells
  118. An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment
  119. Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells
  120. Preparation of a novel radiotracer targeting the EphB4 receptor via radiofluorination using spiro azetidinium salts as precursor
  121. Biological characterization of novel nitroimidazole-peptide conjugates in vitr o and in vivo
  122. Novel Tumor Pretargeting System Based on Complementaryl-Configured Oligonucleotides
  123. In Vivo Examination of an Injectable Hydrogel System Crosslinked by Peptide-Oligosaccharide Interaction in Immunocompetent Nude Mice
  124. Human Endothelial Cell Models in Biomaterial Research
  125. Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”
  126. Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy
  127. A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform
  128. Surface charge and particle size determine the metabolic fate of dendritic polyglycerols
  129. The why and how of amino acid analytics in cancer diagnostics and therapy
  130. Technetium-99m based small molecule radiopharmaceuticals and radiotracers targeting inflammation and infection
  131. Development of a18F-labeled Diaryl-Substituted Dihydropyrrolo[3,2,1-hi]indole as Potential Probe for Functional Imaging of Cyclooxygenase-2 with PET
  132. S100 proteins and scavenger receptors: what's going on?
  133. Zwitterionic Polymer-Coated Ultrasmall Superparamagnetic Iron Oxide Nanoparticles with Low Protein Interaction and High Biocompatibility
  134. Extracellular S100A4 affects endothelial cell integrity and stimulates transmigration of A375 melanoma cells
  135. Corrigendum: Synthesis and Kinetic Characterisation of Water-Soluble Fluorogenic Acyl Donors for Transglutaminase 2
  136. Synthesis and Kinetic Characterisation of Water-Soluble Fluorogenic Acyl Donors for Transglutaminase 2
  137. Development of Antioxidant COX-2 Inhibitors as Radioprotective Agents for Radiation Therapy—A Hypothesis-Driven Review
  138. Interaction of extracellular S100A4 with RAGE prompts prometastatic activation of A375 melanoma cells
  139. 177Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment
  140. Protective effects of 2,3-diaryl-substituted indole-based cyclooxygenase-2 inhibitors on oxidative modification of human low density lipoproteins in vitro
  141. Controlled immobilization of His-tagged proteins for protein-ligand interaction experiments using Ni2+-NTA layer on glass surfaces
  142. Gelatin-based Hydrogel Degradation and Tissue Interactionin vivo: Insights from Multimodal Preclinical Imaging in Immunocompetent Nude Mice
  143. Multimodal Somatostatin Receptor Theranostics Using [64Cu]Cu-/[177Lu]Lu-DOTA-(Tyr3)octreotate and AN-238 in a Mouse Pheochromocytoma Model
  144. Radiopharmacological characterization of 64Cu-labeled α-MSH analogs for potential use in imaging of malignant melanoma
  145. 68Ga- und 177Lu-markierte Bisphosphonate als Knochenmetastasen-Theranostika
  146. Development of indazolylpyrimidine derivatives as high-affine EphB4 receptor ligands and potential PET radiotracers
  147. Novel (pyrazolyl)benzenesulfonamides with a nitric oxide-releasing moiety as selective cyclooxygenase-2 inhibitors
  148. Copper(II) Cyclam Complexes withN-­Propionic Acid Pendant Arms
  149. Effects of pulmonary acid aspiration on the regional pulmonary blood flow within the first hour after injury: An observational study in rats1
  150. 18F-Labeled 1,4-Dioxa-8-azaspiro[4.5]decane Derivative: Synthesis and Biological Evaluation of a σ1Receptor Radioligand with Low Lipophilicity as Potent Tumor Imaging Agent
  151. Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probes
  152. Synthesis and Biodistribution Studies of 3 H- and 64 Cu-Labeled Dendritic Polyglycerol and Dendritic Polyglycerol Sulfate
  153. Diaryl-Substituted (Dihydro)pyrrolo[3,2,1-hi]indoles, a Class of Potent COX-2 Inhibitors with Tricyclic Core Structure
  154. Reduced pulmonary blood flow in regions of injury 2 hours after acid aspiration in rats
  155. Optical imaging of COX-2: Studies on an autofluorescent 2,3-diaryl-substituted indole-based cyclooxygenase-2 inhibitor
  156. Cyclopeptides containing the DEKS motif as conformationally restricted collagen telopeptide analogues: synthesis and conformational analysis
  157. Novel indole-based sigma-2 receptor ligands: synthesis, structure–affinity relationship and antiproliferative activity
  158. Biocompatibility and inflammatory response in vitro and in vivo to gelatin-based biomaterials with tailorable elastic properties
  159. In Vivo Fluorescence Imaging and Urinary Monoamines as Surrogate Biomarkers of Disease Progression in a Mouse Model of Pheochromocytoma
  160. Radiofluorination and first radiopharmacological characterization of a SWLAY peptide-based ligand targeting EphA2
  161. Bispidine Dioxotetraaza Macrocycles: A New Class of Bispidines for 64Cu PET Imaging
  162. Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy
  163. Metastatic potential of B16-F10 melanoma cells is enhanced by extracellular S100A4 derived from RAW264.7 macrophages
  164. ChemInform Abstract: Tissue Transglutaminase: An Emerging Target for Therapy and Imaging
  165. Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential
  166. 2,3-Diaryl-substituted indole based COX-2 inhibitors as leads for imaging tracer development
  167. Organotypical vascular model for characterization of radioprotective compounds: Studies on antioxidant 2,3-diaryl-substituted indole-based cyclooxygenase-2 inhibitors
  168. Synthesis and radiopharmacological evaluation of 64Cu-labeled bombesin analogs featuring a bis(2-pyridylmethyl)-1,4,7-triazacyclononane chelator
  169. Tissue transglutaminase: An emerging target for therapy and imaging
  170. Pulmonary Blood Flow Increases in Damaged Regions Directly after Acid Aspiration in Rats
  171. Optimization of Pentadentate Bispidines as Bifunctional Chelators for64Cu Positron Emission Tomography (PET)
  172. Synthesis and Radiopharmacological Characterisation of a Fluorine-18-Labelled Azadipeptide Nitrile as a Potential PET Tracer for in vivo Imaging of Cysteine Cathepsins
  173. Radiolabeled COX-2 Inhibitors for Non-Invasive Visualization of COX-2 Expression and Activity — A Critical Update
  174. Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells
  175. An Efficient Bioorthogonal Strategy Using CuAAC Click Chemistry for Radiofluorinations of SNEW Peptides and the Role of Copper Depletion
  176. Experimental hypoxia does not influence gene expression and protein synthesis of Eph receptors and ephrin ligands in human melanoma cells in vitro
  177. 2-Carbaborane-3-phenyl-1H-indoles-Synthesis via McMurry Reaction and Cyclooxygenase (COX) Inhibition Activity
  178. Copper(ii) chemistry of the functionalized macrocycle cyclam tetrapropionic acid
  179. Visualization of cyclooxygenase-2 using a 2,3-diarylsubstituted indole-based inhibitor and confocal laser induced cryofluorescence microscopy at 20K in melanoma cells in vitro
  180. 18F-Labeled phosphopeptide-cell-penetrating peptide dimers with enhanced cell uptake properties in human cancer cells
  181. Protein and non-protein biomarkers in melanoma: a critical update
  182. Fluorine-18 Radiolabeling and Radiopharmacological Characterization of a Benzodioxolylpyrimidine-based Radiotracer Targeting the Receptor Tyrosine Kinase EphB4
  183. Radiosynthesis of a 18F-labeled 2,3-diarylsubstituted indole via McMurry coupling for functional characterization of cyclooxygenase-2 (COX-2) in vitro and in vivo
  184. Design, Evaluation, and Comparison of Ghrelin Receptor Agonists and Inverse Agonists as Suitable Radiotracers for PET Imaging
  185. Irradiation affects cellular properties and Eph receptor expression in human melanoma cells
  186. Site-selective radiolabeling of peptides by 18F-fluorobenzoylation with [18F]SFB in solution and on solid phase: a comparative study
  187. Cyclin-Dependent Kinases (Cdk) as Targets for Cancer Therapy and Imaging
  188. Specific Targeting of Hypoxic Tumor Tissue with Nitroimidazole-Peptide Conjugates
  189. Synthesis of an 18F-labeled cyclin-dependent kinase-2 inhibitor
  190. Automated radiosynthesis of the thiol-reactive labeling agent N-[6-(4-[18F]fluorobenzylidene)aminooxyhexyl]maleimide ([18F]FBAM)
  191. Copper-mediated cross-linking of S100A4, but not of S100A2, results in proinflammatory effects in melanoma cells
  192. Phosphopeptides with improved cellular uptake properties as ligands for the polo-box domain of polo-like kinase 1
  193. A novel tetrabranched neurotensin(8–13) cyclam derivative: Synthesis, 64Cu-labeling and biological evaluation
  194. Synthesis, characterization and biological evaluation of [188Re(N)(cys∼)(PNP)]+/0 mixed-ligand complexes as prototypes for the development of 188Re(N)-based target-specific radiopharmaceuticals
  195. Synthesis and evaluation of 1,5-diaryl-substituted tetrazoles as novel selective cyclooxygenase-2 (COX-2) inhibitors
  196. Expression, purification and fluorine-18 radiolabeling of recombinant S100A4: a potential probe for molecular imaging of receptor for advanced glycation endproducts in vivo?
  197. S100 proteins in health and disease
  198. Modulation of Adrenal Aldosterone Release by Oxidative Modification of Low-Density Lipoprotein
  199. S100A2 in cancerogenesis: a friend or a foe?
  200. Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging
  201. Synthesis of neurotensin(8–13)–phosphopeptide heterodimers via click chemistry
  202. Scavenger receptors are associated with cellular interactions of S100A12 in vitro and in vivo
  203. Improved multimodality imaging using alginate molding in xenograft tumor models
  204. Effects of posture on regional pulmonary blood flow in rats as measured by PET
  205. Radiosynthesis and radiopharmacological evaluation of cyclin-dependent kinase 4 (Cdk4) inhibitors
  206. Eph receptors and ephrins: bloody players
  207. Influence of irradiation on metabolism and metastatic potential of B16-F10 melanoma cells
  208. Validation of 99mTc-labeled “4+1” fatty acids for myocardial metabolism and flow imaging
  209. Validation of 99mTc-labeled “4+1” fatty acids for myocardial metabolism and flow imaging
  210. Radiosynthesis and radiopharmacological evaluation of [N-methyl-11C]Org 34850 as a glucocorticoid receptor (GR)-binding radiotracer
  211. Synthesis and cyclooxygenase inhibition of various (aryl-1,2,3-triazole-1-yl)-methanesulfonylphenyl derivatives
  212. Cell Cycle Regulating Kinase Cdk4 as a Potential Target for Tumor Cell Treatment and Tumor Imaging
  213. Erratum
  214. Fluorine-18 labeling of phosphopeptides: A potential approach for the evaluation of phosphopeptide metabolism in vivo
  215. Reduction of Arteriosclerotic Nanoplaque Formation and Size by n-3 Fatty Acids in Patients after Valvular Defect Operation
  216. Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study
  217. Prediabetic and diabetic in vivo modification of circulating low-density lipoprotein attenuates its stimulatory effect on adrenal aldosterone and cortisol secretion
  218. Synthesis and evaluation in vitro and in vivo of a 11C-labeled cyclooxygenase-2 (COX-2) inhibitor
  219. Radiolabeled Glucocorticoids as Molecular Probes for Imaging Brain Glucocorticoid Receptors by Means of Positron Emission Tomography (PET)
  220. Synthesis and Application of [18F]FDG-Maleimidehexyloxime ([18F]FDG-MHO): A [18F]FDG-Based Prosthetic Group for the Chemoselective18F-Labeling of Peptides and Proteins†
  221. Human S100A12: a novel key player in inflammation?
  222. Systematic comparison of two novel, thiol-reactive prosthetic groups for 18F labeling of peptides and proteins with the acylation agent succinimidyl-4-[18F]fluorobenzoate ([18F]SFB)
  223. Expression, purification and fluorine-18 radiolabeling of recombinant S100 proteins—potential probes for molecular imaging of receptor for advanced glycation endproducts (RAGE) in vivo
  224. Glycoxidation of Low Density Lipoprotein in Impaired Glucose Tolerance: Implications for the Pathogenesis of Diabetic Vascular Disease
  225. Yttrium-86-labelled human serum albumin microspheres: relation of surface structure with in vivo stability
  226. Modified “4 + 1” Mixed Ligand Technetium-Labeled Fatty Acids for Myocardial Imaging: Evaluation of Myocardial Uptake and Biodistribution
  227. L-Type Amino Acid Transporters LAT1 and LAT4 in Cancer: Uptake of 3-O-Methyl-6- 18F-Fluoro-L-Dopa in Human Adenocarcinoma and Squamous Cell Carcinoma In Vitro and In Vivo
  228. Localized proton magnetic resonance spectroscopy of lipids in adipose tissue at high spatial resolution in mice in vivo
  229. Factors influencing the formation of small dense low-density lipoprotein particles in dependence on the presence of the metabolic syndrome and on the degree of glucose intolerance
  230. Experimental hypoxia is a potent stimulus for radiotracer uptake in vitro: Comparison of different tumor cells and primary endothelial cells
  231. Myocardial uptake and biodistribution of newly designed technetium-labelled fatty acid analogues
  232. Synthesis and radiopharmacological characterization of [11C]AL-438 as a nonsteroidal ligand for imaging brain glucocorticoid receptors
  233. Glycoxidised LDL isolated from subjects with impaired glucose tolerance increases CD36 and peroxisome proliferator–activator receptor γ gene expression in macrophages
  234. Labeling of low-density lipoproteins using the 18F-labeled thiol-reactive reagent N-[6-(4-[18F]fluorobenzylidene)aminooxyhexyl]maleimide
  235. Lipid transfer protein activities in subjects with impaired glucose tolerance
  236. Synthesis and Biological Evaluation of a New Type of99mTechnetium-Labeled Fatty Acid for Myocardial Metabolism Imaging
  237. Biodistribution and catabolism of 18F-labeled N-ε-fructoselysine as a model of Amadori products
  238. Positron emission tomography in food sciences
  239. Glucose-Induced Enhancement of Hemin-Catalyzed LDL Oxidation In Vitro and In Vivo
  240. Small animal positron emission tomography in food sciences
  241. Catabolism of native and oxidized low density lipoproteins: in vivo insights from small animal positron emission tomography studies
  242. Synthesis and biodistribution of an 18F-labelled resveratrol derivative for small animal positron emission tomography
  243. Biodistribution and catabolism of 18F-labelled isopeptide Nɛ-(γ-glutamyl)-L-lysine
  244. Fluorine-18 radiolabeling of low-density lipoproteins: a potential approach for characterization and differentiation of metabolism of native and oxidized low-density lipoproteins in vivo
  245. Oxidativ modifizierte Lipoproteine und deren Antik�rper bei Patienten mit Antiphospholipidsyndrom und Systemischem Lupus erythematodes
  246. The pivotal role of scavenger receptor CD36 and phagocyte-derived oxidants in oxidized low density lipoprotein-induced adhesion to endothelial cells
  247. The protective effects of HDL and its constitutents against neutrophil respiratory burst activation by hypochlorite-oxidized LDL
  248. The effect of garlic on arteriosclerotic nanoplaque formation and size
  249. Analysis of non-protein amino acids as specific markers of low density lipoprotein apolipoprotein B-100 oxidation in human atherosclerotic lesions: the use ofN(O)-ethoxycarbonyl trifluoroethyl ester derivatives and GC-MS1
  250. Analysis of 6-hydroxy-2-aminocaproic acid (HACA) as a specific marker of protein oxidation: The use of N(O,S)-ethoxycarbonyl trifluoroethyl ester derivatives and gas chromatography/mass spectrometry
  251. Measurement of 5-hydroxy-2-aminovaleric acid as a specific marker of metal catalysed oxidation of proline and arginine residues of low density lipoprotein apolipoprotein B-100 in human atherosclerotic lesions
  252. Lack of Association between Serum Paraoxonase 1 Activities and Increased Oxidized Low-Density Lipoprotein Levels in Impaired Glucose Tolerance and Newly Diagnosed Diabetes Mellitus
  253. Analysis of 3-chlorotyrosine as a specific marker of protein oxidation: the use ofN(O,S)-ethoxycarbonyltrifluoroethyl ester derivatives and gas chromatography/mass spectrometry
  254. Validation of different chemilumigenic substrates for detecting extracellular generation of reactive oxygen species by phagocytes and endothelial cells
  255. In Vivo Evidence for Increased Oxidation of Circulating LDL in Impaired Glucose Tolerance
  256. Protective Effects of Native But Not Oxidized High-Density Lipoprotein against Proinflammatory Respiratory Burst Activities of Polymorphonuclear Leukocytes Induced by Hypochlorite-Oxidized Low-Density Lipoprotein
  257. UVB-Induced Conversion of 7-Dehydrocholesterol to 1α,25-Dihydroxyvitamin D3 in an In Vitro Human Skin Equivalent Model
  258. Homocysteine levels in patients treated with lipid apheresis: effect of a vitamin therapy
  259. Different susceptibility to oxidation of proline and arginine residues of apolipoprotein B-100 among subspecies of low density lipoproteins
  260. Oxidation of Apolipoprotein B-100 in Circulating LDL Is Related to LDL Residence Time
  261. Impaired glucose tolerance (IGT) is not associated with disturbed homocysteine metabolism
  262. Conversion of vitamin D3 to 1alpha,25-dihydroxyvitamin D3 in human skin equivalents
  263. Measurement of 5-Hydroxy-2-aminovaleric Acid as a Specific Marker of Iron-Mediated Oxidation of Proline and Arginine Side-Chain Residues of Low-Density Lipoprotein Apolipoprotein B-100
  264. Urate modifies lipoprotein oxidation
  265. Human secretory group IIA phospholipase A2 is associated with lipid metabolism
  266. Störungen des Lipid- und Lipoproteinstoffwechsels
  267. Metabolic Basis of Low High Density Lipoprotein in Subjects with Impaired Glucose Tolerance
  268. Very Low Density Lipoprotein Overproduction Is Maximally Expressed in Early Insulin Resistant States
  269. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance
  270. Human keratinocyte line HaCaT metabolizes 1α-hydroxyvitamin D3 and vitamin D3 to 1α,25-dihydroxyvitamin D3 (calcitriol)
  271. Determination of Total Homocysteine
  272. Hypochlorite-modified low-density lipoprotein stimulates human polymorphonuclear leukocytes for enhanced production of reactive oxygen metabolites, enzyme secretion, and adhesion to endothelial cells
  273. Stable isotope ratio analysis of amino acids: the use ofN(O,S)-ethoxycarbonyl trifluoroethyl ester derivatives and gas chromatography/mass spectrometry
  274. Rapid Determination of Total Homocysteine in Human Plasma by Using N(O,S)-Ethoxycarbonyl Ethyl Ester Derivatives and Gas Chromatography–Mass Spectrometry,
  275. Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition
  276. Recovery of Cholesterol and Triacylglycerol in Very-Fast Ultracentrifugation of Human Lipoproteins in a Large Range of Concentrations
  277. Very-fast ultracentrifugation of human plasma lipoproteins: influence of the centrifugal field on lipoprotein composition